Abstract
Background: Epilepsy is a disease of the central nervous system that affects approximately 50 million individuals worldwide. Although several new drugs have been marketed in the last 25 years, almost one-third of patients are not protected. In many cases, currently available drugs produce undesirable side effects. As a result, a need exists for novel anticonvulsants with unique mechanisms of action and minimal side effects.
Methods: A mixed anhydride coupling procedure and standard deprotection procedures were utilized to prepare 36 α-amino acid amides. All final products were evaluated in mice and rats utilizing a standard battery of anticonvulsant tests. Results: α-Amino acids containing a 2,6-dimethylanilide group exhibited anticonvulsant activity in the maximal electroshock seizure test and 6 Hz test in mice and rats. A small, branched-chain on the α- carbon generally maintained or enhanced anticonvulsant activity in the maximal electroshock seizure test. The (R)-α-amino acid amides were typically more potent and slightly more neurotoxic than the corresponding (S)-enantiomers. The valine dimethylanilide (R)-42 was highly active in the MES test in mice (ED50 = 3.6mg/kg) and rats (ED50 = 3.8 mg/kg). (R)-42 also demonstrated excellent anticonvulsant activity in the 6 Hz, picrotoxin, and corneal kindled mouse tests. Furthermore, (R)-42 did not lower seizure threshold when evaluated in the intravenous metrazol seizure test. Conclusion: α-Amino acid 2,6-dimethylanilides exhibited potent activity in a variety of anticonvulsant tests in mice and rats. The valine derivative (R)-42 represents a promising compound for potential use in complex partial seizures.Keywords: α-amino acid amides, 2, 6-dimethylanilide, anticonvulsant, 6 Hz test, MES test, central nervous system.
Graphical Abstract
[http://dx.doi.org/10.1016/j.nurt.2009.01.001] [PMID: 19332332]
[http://dx.doi.org/10.1001/jama.291.5.605] [PMID: 14762040]
[http://dx.doi.org/10.2174/1573407213666161214162149]
[http://dx.doi.org/10.2174/1573407212666160527104556]
[http://dx.doi.org/10.2174/1573407210666140307011414]
[http://dx.doi.org/10.1016/S0223-5234(99)80072-5]
[http://dx.doi.org/10.1016/S0223-5234(00)01206-X] [PMID: 11337105]
[http://dx.doi.org/10.1021/jm100508m] [PMID: 20614888]
[http://dx.doi.org/10.1021/jm200759t] [PMID: 21861463]
[http://dx.doi.org/10.1021/jm2004305] [PMID: 21639114]
[http://dx.doi.org/10.1002/chir.530050306] [PMID: 8338723]
[http://dx.doi.org/10.1021/jm061078e] [PMID: 17373780]
[PMID: 1257275]
[http://dx.doi.org/10.1016/j.drudis.2010.06.014] [PMID: 20603226]
[http://dx.doi.org/10.1016/S0920-1211(01)00302-3] [PMID: 11738929]
[http://dx.doi.org/10.1016/j.seizure.2011.01.003] [PMID: 21292505]
[http://dx.doi.org/10.1016/j.eplepsyres.2010.09.002] [PMID: 20951004]
[http://dx.doi.org/10.1113/jphysiol.1992.sp018998] [PMID: 1317428]
[http://dx.doi.org/10.1016/j.tet.2007.02.037]
[http://dx.doi.org/10.1021/jm00196a005] [PMID: 513064]
[http://dx.doi.org/10.1002/jhet.536]
[http://dx.doi.org/10.3389/fphar.2011.00068] [PMID: 22053156]